摘要
目的评价硝酸异山梨酯、缬沙坦、依那普利联合治疗肺心病失代偿期的疗效。方法治疗组在常规治疗基础上联合口服依那普利5～10mg/d、缬沙坦20～40mg/d、硝酸异山梨酯30～60mg/d,根据患者血压和耐受情况调整剂量。两组患者治疗前后分别进行CAPS评分,并观察患者的临床疗效、住院时间和不良反应发生情况。结果治疗组的总有效率、住院时间均优于对照组(P>0.05);不良反应无统计学意义(P>0.05)。结论硝酸异山梨酯、依那普利、缬沙坦联合治疗肺心病失代偿期疗效好。
Objective To evaluate the Isosorbide dinitrate、valsartan,enalapril combination therapy efficacy in pulmonary heart disease.Methods On the conventional treatment group based on the combined treatment of oral enalapril 5-10mg/d,valsartan 20-40mg/d,Isosorbide dinitrate 30~60mg/d,According to adjust blood pressure and tolerated dose.Two groups of patients before and after treatment operated CAPS score,and to observe the occurrence of adverse reactions in patients.Results Treatment group was higher than control group in the total effective rate and hospital time（P〉0.05）.2 groups of adverse events was similar（P〉0.05）.Conclusion Isosorbide dinitrate combination with Enalapril and valsartan has good curative effect for pulmonale decompensated period.
出处
《实用心脑肺血管病杂志》
2012年第9期1495-1496,共2页
Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease
关键词
硝酸异山梨酯
依那普利
缬沙坦
肺心病
Isosorbide dinitrate
Enalapril
Valsartan
Pulmonary heart disease
